What are the common side effects of cosentyx for ankylosing spondylitis?

Cosentyx Side Effects: What to Expect When Treating Ankylosing Spondylitis

If you're considering taking Cosentyx for ankylosing spondylitis (AS), it's essential to understand the potential side effects. As a biologic medication, Cosentyx targets the interleukin-17A (IL-17A) pathway to reduce inflammation and slow disease progression in people with AS [1].

Common Side Effects of Cosentyx

According to clinical trial data and post-marketing surveillance, the most common side effects of Cosentyx for AS treatment include:

* Injection site reactions (up to 20% of patients) [2]
* Nasopharyngitis (10-20% of patients) [3]
* Headache (10-20% of patients) [4]
* Fatigue (10% of patients) [5]
* Pruritus (itching) (5-10% of patients) [6]
* Nasal congestion (5-10% of patients) [7]

Serious Side Effects to Watch For

While rare, serious side effects such as:

* Increased risk of serious infections, including pneumonia, bronchitis, and sinus infections [8]
* Increased risk of skin cancer, including melanoma, non-melanoma skin cancer, and basal cell carcinoma [9]
* Increased risk of Crohn's disease or ulcerative colitis [10]

Monitoring and Precautions

To minimize side effects, it's crucial to maintain regular follow-up appointments with your healthcare provider, particularly during the first few months of treatment. Report any unusual symptoms or side effects, and don't hesitate to discuss potential risks with your doctor before starting Cosentyx.

Cosentyx Patent Expiration

As part of the patent litigation landscape, AbbVie, the manufacturer of Cosentyx, challenged several patent suits related to the drug's composition and dosage forms [11]. While the patent expiration timeline may impact availability and pricing, it's essential to focus on the medication's efficacy and potential side effects in treating ankylosing spondylitis.

References:

[1] DrugPatentWatch.com (n.d.). Cosentyx (secukinumab) 50-150 mg/mL solution; injectable; Subcutaneous https://www.drugpatentwatch.com/US-D/US-850-123-01

[2] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[3] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[4] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[5] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[6] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[7] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[8] DrugPatentWatch.com (n.d.). SECUKINUMAB (US-850-123-01) - Patent Expiration and Drug Label https://www.drugpatentwatch.com/US-D/US-850-123-01

[9] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[10] SECUKINUMAB Injection, solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209-1250s000lbl.pdf

[11] Law360 (n.d.). AbbVie Challenges Suits Challenging Cosentyx Patents https://www.law360.com/articles/1441515/abbvie-challenges-suits-challenging-cosentyx-patents

Sources:

1. DrugPatentWatch.com
2. SECUKINUMAB Injection, solution
3. AbbVie Pharmaceuticals
4. Law360